company background image
603229 logo

Zhejiang Ausun Pharmaceutical SHSE:603229 Stock Report

Last Price

CN¥8.01

Market Cap

CN¥6.7b

7D

-4.0%

1Y

-32.4%

Updated

13 Oct, 2024

Data

Company Financials

Zhejiang Ausun Pharmaceutical Co., Ltd.

SHSE:603229 Stock Report

Market Cap: CN¥6.7b

603229 Stock Overview

Engages in the research and development, process development, manufacture, and sale of APIs and pharmaceutical intermediates.

603229 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance4/6
Financial Health5/6
Dividends2/6

Zhejiang Ausun Pharmaceutical Co., Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Zhejiang Ausun Pharmaceutical
Historical stock prices
Current Share PriceCN¥8.01
52 Week HighCN¥11.75
52 Week LowCN¥5.76
Beta-0.029
11 Month Change20.09%
3 Month Change13.46%
1 Year Change-32.36%
33 Year Change-16.96%
5 Year Change146.66%
Change since IPO228.23%

Recent News & Updates

There's No Escaping Zhejiang Ausun Pharmaceutical Co., Ltd.'s (SHSE:603229) Muted Earnings Despite A 37% Share Price Rise

Oct 08
There's No Escaping Zhejiang Ausun Pharmaceutical Co., Ltd.'s (SHSE:603229) Muted Earnings Despite A 37% Share Price Rise

Improved Earnings Required Before Zhejiang Ausun Pharmaceutical Co., Ltd. (SHSE:603229) Shares Find Their Feet

Jul 31
Improved Earnings Required Before Zhejiang Ausun Pharmaceutical Co., Ltd. (SHSE:603229) Shares Find Their Feet

Recent updates

There's No Escaping Zhejiang Ausun Pharmaceutical Co., Ltd.'s (SHSE:603229) Muted Earnings Despite A 37% Share Price Rise

Oct 08
There's No Escaping Zhejiang Ausun Pharmaceutical Co., Ltd.'s (SHSE:603229) Muted Earnings Despite A 37% Share Price Rise

Improved Earnings Required Before Zhejiang Ausun Pharmaceutical Co., Ltd. (SHSE:603229) Shares Find Their Feet

Jul 31
Improved Earnings Required Before Zhejiang Ausun Pharmaceutical Co., Ltd. (SHSE:603229) Shares Find Their Feet

Improved Earnings Required Before Zhejiang Ausun Pharmaceutical Co., Ltd. (SHSE:603229) Stock's 27% Jump Looks Justified

Mar 06
Improved Earnings Required Before Zhejiang Ausun Pharmaceutical Co., Ltd. (SHSE:603229) Stock's 27% Jump Looks Justified

Shareholder Returns

603229CN PharmaceuticalsCN Market
7D-4.0%-5.7%-4.5%
1Y-32.4%-8.5%-2.6%

Return vs Industry: 603229 underperformed the CN Pharmaceuticals industry which returned -8.5% over the past year.

Return vs Market: 603229 underperformed the CN Market which returned -2.6% over the past year.

Price Volatility

Is 603229's price volatile compared to industry and market?
603229 volatility
603229 Average Weekly Movement6.8%
Pharmaceuticals Industry Average Movement6.9%
Market Average Movement7.4%
10% most volatile stocks in CN Market11.2%
10% least volatile stocks in CN Market5.2%

Stable Share Price: 603229 has not had significant price volatility in the past 3 months compared to the CN market.

Volatility Over Time: 603229's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20101,174Zhiguo Zhengwww.ausunpharm.com

Zhejiang Ausun Pharmaceutical Co., Ltd. engages in the research and development, process development, manufacture, and sale of APIs and pharmaceutical intermediates. It offers fluorine products, prostaglandins, antimicrobials, and oncology products. The company also provides products for liver disease, respiratory system, and cardiac and cerebral vessels, as well as CNS indications.

Zhejiang Ausun Pharmaceutical Co., Ltd. Fundamentals Summary

How do Zhejiang Ausun Pharmaceutical's earnings and revenue compare to its market cap?
603229 fundamental statistics
Market capCN¥6.65b
Earnings (TTM)CN¥273.54m
Revenue (TTM)CN¥840.44m

24.3x

P/E Ratio

7.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
603229 income statement (TTM)
RevenueCN¥840.44m
Cost of RevenueCN¥372.90m
Gross ProfitCN¥467.55m
Other ExpensesCN¥194.01m
EarningsCN¥273.54m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

Oct 30, 2024

Earnings per share (EPS)0.33
Gross Margin55.63%
Net Profit Margin32.55%
Debt/Equity Ratio8.6%

How did 603229 perform over the long term?

See historical performance and comparison

Dividends

1.1%

Current Dividend Yield

27%

Payout Ratio